Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/14/2013

alatin Technologies, Inc., such as statements about clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates and market potential for product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.  Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

 PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statements of Operations(unaudited)Three Months Ended December 31,Six Months Ended December 31,2012201120122011REVENUES:

$
,555$
,492$
,361$
38,709OPERATING EXPENSES:Research and development

2,445,7702,693,0674,78
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... N.J. , July 24, 2014 ... provider of regulatory and ethical review services for ... Alliance Biosciences. Formerly a division of ... was the leading biosafety and biosecurity consulting firm ... With this addition, WCG,s biosafety division – WCG ...
(Date:7/24/2014)... 24, 2014   Cypher Genomics, Inc., ... of Adam Simpson as president and ... and comprehensive annotation and interpretation of individual human ... "Cypher,s technology has the potential to play ... diagnostic accuracy, optimizing therapeutic approaches and reducing adverse ...
(Date:7/23/2014)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) today ... For the second quarter ended June ... $7.0 million, or $0.10 per share, compared to a ... for the same period in 2013. As of June ... securities and interest receivable of $236.7 million. ...
(Date:7/23/2014)... Ill. , July 23, 2014 /PRNewswire/ ... (SNA™) constructs as gene regulatory and immunotherapeutic ... has joined AuraSense Therapeutics, executive leadership ... 11. Prior to joining AuraSense ... and Chief Financial Officer of Cellular Dynamics ...
Breaking Biology Technology:WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2
... Optimal for Expansion in Medical Imaging Management , ... BIRMINGHAM, Ala., June 4 Optimal Reading Services Group, ... services for hospitals, imaging centers and radiology groups, announced ... made a substantial investment in Optimal. The investment provides ...
... 4 Ratcliff promoted Jorge Burbano to senior associate and ... this month. The award-winning firm ( http://www.ratcliffarch.com ... design and planning services to healthcare, academic and civic clients ... LEED(R) AP, has more than 20 years of architectural design ...
... , , SAN DIEGO, June 4 Neurocrine ... Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences ... Conference in New York. , , The live ... Eastern Time (ET)/10:30 a.m. Pacific Time (PT). The presentation ...
Cached Biology Technology:Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners 2Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners 3Ratcliff Promotes Jorge Burbano to Senior Associate; Tess Kavanagh and Tony Keung to Associate 2Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference 2
(Date:7/24/2014)... NEW BRUNSWICK, N.J. A yearlong study funded by ... at the Edward J. Bloustein School of Planning and ... property owners in Sandy-affected towns are skeptical about the ... 400 online survey respondents, 45 percent indicated they were ... town affected by Superstorm Sandy would be rebuilt better ...
(Date:7/24/2014)... is available in German . ... 300 million asthma sufferers worldwide, a further 600 million ... of the global population contending with allergic rhinitis (allergic ... also affect other organs and parts of the body ... intestine (in the form of inflammatory bowel diseases such ...
(Date:7/24/2014)... July 24, 2014 NXT-ID, Inc., (NXTD: OTCQB) a biometric ... its next generation smart wallet, Wocket™, was recently the topic of  ... interviewed Gino Pereira , CEO of NXT-ID, ... Mr. Gino Pereira explains ... of credit cards and walks host Anita Finley ...
Breaking Biology News(10 mins):Rutgers study explores attitudes, preferences toward post-Sandy rebuilding 2New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4
... Scientists (AAPS) is a professional, scientific society of ... and other research institutes worldwide. Founded in 1986, ... exchange of knowledge among scientists to enhance their ... programs, on-going education, information resources, opportunities for networking, ...
... has to work 17 times harder to catch the same amount ... were powered by sail, according to new research. Researchers from ... UK Government data on the amount of fish caught and the ... to analyse the change in fish stocks since 1889. ...
... An experienced fruit fly researcher can tell at a glance ... distinct pigmentation pattern on a fly,s body (a type of bristle ... genitalia are dead giveaways. But most of the fly,s body parts ... no idea whether "maleness" or "femaleness" extended to all of the ...
Cached Biology News:Fishing fleet working 17 times harder than in 1880s to make same catch 2Male or female? In flies, some cells can't tell 2Male or female? In flies, some cells can't tell 3
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Serum Albumin protein through lysine by amide bonds....
EoProbe Eosinophil Staining Kit, 1 Kit...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
...
Biology Products: